Abstract
INTRODUCTION: Breast cancer is a serious health problem; 1.3 million women worldwide will be diagnosed with breast cancer each year, 465,000 will die annually. In Mexico, the disease represents 49% of neoplasms in women. Metastatic disease is the main cause of death in women with breast cancer (BC) making it important to identify chemotherapy (CT) schedules that offer the best response rate and palliation.
PATIENTS AND METHODS: From October 2009 to August 2011, 37 breast cancer patients previously treated for metastatic disease (BC) and a minimum of two prior CT lines were treated with gemcitabine (G) (Total dose 200mg) plus Cisplatin ( C ) (Total dose 50mg) weekly. Patients were included following histological confirmation of breast cancer as the primary site and disease had to be clinically measurable or determined according to the RECIST method by ultrasound or conventional computer tomography (CT).
RESULTS: The median age was 52 years ; 92% were ductal carcinoma; all patients presented evidence of disease progression; received another treatment regimen and palliative chemotherapy in various lines; all patients were exposed to regimens with anthracyclines and 12 (32.4%) received taxanes. 51 % had received surgical intervention. The median metastatic site was 2 (range 1-4) the most frequent metastatic sites being the lung (35 %), liver (18.9 %) and central nervous system (16.2 %).
CONCLUSION: The weekly administration of low-dose gemcitabine and conventional dose of cisplatin is an active and well-tolerated regimen with response rates similar to those reported in most other treatment options.
Keywords: Gemcitabine, Cisplatin, Breast cancer, Metastic Keywords.
Current Cancer Therapy Reviews
Title:Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients
Volume: 9 Issue: 2
Author(s): Flavia Morales-Vásquez, Horacio Noé López-Basave, Carmen Méndez-Herrera, Laura L. Tirado-Gómez, Eva Ruvalcaba Limón and Sergio A. Rodríguez-Cuevas
Affiliation:
Keywords: Gemcitabine, Cisplatin, Breast cancer, Metastic Keywords.
Abstract: INTRODUCTION: Breast cancer is a serious health problem; 1.3 million women worldwide will be diagnosed with breast cancer each year, 465,000 will die annually. In Mexico, the disease represents 49% of neoplasms in women. Metastatic disease is the main cause of death in women with breast cancer (BC) making it important to identify chemotherapy (CT) schedules that offer the best response rate and palliation.
PATIENTS AND METHODS: From October 2009 to August 2011, 37 breast cancer patients previously treated for metastatic disease (BC) and a minimum of two prior CT lines were treated with gemcitabine (G) (Total dose 200mg) plus Cisplatin ( C ) (Total dose 50mg) weekly. Patients were included following histological confirmation of breast cancer as the primary site and disease had to be clinically measurable or determined according to the RECIST method by ultrasound or conventional computer tomography (CT).
RESULTS: The median age was 52 years ; 92% were ductal carcinoma; all patients presented evidence of disease progression; received another treatment regimen and palliative chemotherapy in various lines; all patients were exposed to regimens with anthracyclines and 12 (32.4%) received taxanes. 51 % had received surgical intervention. The median metastatic site was 2 (range 1-4) the most frequent metastatic sites being the lung (35 %), liver (18.9 %) and central nervous system (16.2 %).
CONCLUSION: The weekly administration of low-dose gemcitabine and conventional dose of cisplatin is an active and well-tolerated regimen with response rates similar to those reported in most other treatment options.
Export Options
About this article
Cite this article as:
Morales-Vásquez Flavia, López-Basave Noé Horacio, Méndez-Herrera Carmen, Tirado-Gómez L. Laura, Limón Ruvalcaba Eva and Rodríguez-Cuevas A. Sergio, Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients, Current Cancer Therapy Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573394711309020008
DOI https://dx.doi.org/10.2174/1573394711309020008 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Reality Check: Cancer Stem Cell Route to Cancer
Current Biotechnology Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Current Pharmaceutical Design The Asymmetric [C+NC+CC] Coupling Reaction: Development and Application to Natural Product Synthesis
Current Organic Synthesis A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine
Reviews on Recent Clinical Trials Three-Dimensional Manufactured Supports for Breast Cancer Stem Cell Population Characterization
Current Drug Targets Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs
Current Drug Discovery Technologies Soy Protein Remnants Digested by Gastro-duodenal Proteases can Alter Microbial Interactions and Intestinal Cholesterol Absorption
Current Proteomics Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Electrochemical Nucleic Acid-Based Biosensing of Drugs of Abuse and Pharmaceuticals
Current Medicinal Chemistry CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Comprehending the Role of Endocrine Disruptors in Inducing Epigenetic Toxicity
Endocrine, Metabolic & Immune Disorders - Drug Targets Trypsin and Chymotrypsin Inhibitors in Insects and Gut Leeches
Current Pharmaceutical Design Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry